Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study

Kim, Hee J.; Singer, Giselle; Abittan, Brian J.; Chima, Margot; Kimmel, Grace W.; Bares, Jennifer; Gagliotti, Matthew; Genece, Jordan; Chu, Justin Jang Hann; Wilding, Gregory E.; Lebwohl, Mark

doi:10.1016/j.jaad.2020.12.073

Cited by 13 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After browsing the full texts of the included articles, 136 studies were excluded for the following reasons: improper intervention or comparator ( n = 88), not RCT ( n = 43), no relevant outcomes ( n = 10), full‐text unavailable ( n = 5). Only 28 articles 19,25–51 were eligible for inclusion and progressed to the stage of data extraction. Finally, only 22 studies were included in the data analysis since the others had insufficient data.…”

Section: Resultsmentioning

confidence: 99%

Comparison of NB‐UVB combination therapy regimens for vitiligo: A systematic review and network meta‐analysis

Zhu

Liu

Zhang

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background: Vitiligo was an autoimmune disease and some guidelines for the management of vitiligo encouraged the use of NB-UVB combination therapies to enhance repigmentation. Objectives:To compare the effectiveness of current NB-UVB combination regimen at the improvement in repigmentation through a systematic review and network meta-analysis. Methods:We searched the electronic databases for randomized controlled trials related to NB-UVB combination therapy for vitiligo till October 2022. STATA15.0 software was applied to carrying out data analysis.Results: A total of 28 eligible studies involving 1194 participants were enrolled in the analysis. The NMA results revealed that compared with NB-UVB, carboxytherapy

show abstract

Section: Resultsmentioning

confidence: 99%

Comparison of NB‐UVB combination therapy regimens for vitiligo: A systematic review and network meta‐analysis

Zhu

Liu

Zhang

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…Another randomized split-body trial of 28 patients compared NB-UVB monotherapy with apremilast monotherapy and the combination of both interventions in patients with skin types IV-VI. 5 The highest reduction in VASI was observed in the apremilast and NB-UVB combination group, followed by the NB-UVB monotherapy group, with the apremilast monotherapy group showing the least degree of repigmentation. A few case reports have reported vitiligo stabilization and repigmentation with apremilast therapy.…”

Section: Vitiligomentioning

confidence: 89%

“…The majority of patients (76.6%) in this study had Fitzpatrick skin types I–III. Another randomized split‐body trial of 28 patients compared NB‐UVB monotherapy with apremilast monotherapy and the combination of both interventions in patients with skin types IV–VI 5 . The highest reduction in VASI was observed in the apremilast and NB‐UVB combination group, followed by the NB‐UVB monotherapy group, with the apremilast monotherapy group showing the least degree of repigmentation.…”

Section: Off‐label Dermatological Uses Of Apremilastmentioning

confidence: 99%

Evolving utility of apremilast in dermatological disorders for off-label indications

Mehta

Sharma

Dogra

2022

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Apremilast, a small molecule that acts by inhibition of the phosphodiesterase‐4 enzyme, has been approved by the US Food and Drug Administration for the management of psoriatic arthritis, plaque psoriasis and Behçet disease. The drug has drawn much interest from practising dermatologists in view of its exceptional safety profile and prescription convenience, as evident by the recent surge of literature describing its off‐label indications. This review was carried out with the aim of summarizing the literature on off‐label use of apremilast in dermatology, in order to guide clinicians regarding currently available evidence. The PubMed database was searched using ‘apremilast’ as a keyword in the title. Abstracts were individually screened to determine whether there was a description of an off‐label use of apremilast in dermatology within the article. Randomized controlled trial data were available for vitiligo, alopecia areata, hidradenitis suppurativa and atopic dermatitis. Case series and case reports describing apremilast were also reviewed. Owing to its broad spectrum of immunomodulatory activity, apremilast may be useful in several chronic inflammatory skin diseases recalcitrant to conventional therapies, either alone or in combination with other drugs. Further studies are needed to establish its role in various dermatological indications.

show abstract

“…on with NBUVB and Apremilast 30mg twice a day as compared to either monotherapy over 16 weeks of treatment. 10 There was higher probability of achieving grade 3 or 4 re-pigmenta! on a' er 16 weeks of combined therapy with Apremilast and NB-UVB phototherapy compared with 16 weeks of NB-UVB monotherapy (P=0.001).…”

Section: Vi• Ligomentioning

confidence: 99%

“…ents had minor side-eff ects to Apremilast which they tolerated well. 10 Apremilast has also been shown to halt the progression of disease in progressive non-segmental vi! ligo.…”

Section: Vi• Ligomentioning

confidence: 99%

Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature

Bhatia¹

2022

Nepal J Dermatol Venereol & Leprol

View full text Add to dashboard Cite

Introduction: Apremilast, an oral phosphodiesterase-4 inhibitor, decreases the production of pro-inflammatory cytokines including tumour necrosis factor-α, interleukin-12/23, IL-12, IL-2, and interferon-γ; while upregulating the anti-inflammatory cytokine IL-10. Its pan-immunomodulatory nature has led to its use in managing various immune-mediated dermatoses for non-FDA-approved indications. Objectives: To review and analyze the use of Apremilast in Non-FDA-approved indications in current available literature. Materials and methods: PubMed, EMBASE, SCOPUS, and Google scholar databases were searched with the parameters “Apremilast”, “Apremilast NOT Psoriasis*”, “Apremilast NOT Behçet’s*”, and “Apremilast NOT arthritis*”. A total of 45 relevant articles were chosen for review. Results: We found 22 indications in dermatology where apremilast has been used without FDA approval. The best evidence was for treatment in Atopic Dermatitis, Alopecia Areata, and Hidradenitis Suppurativa, with randomized controlled trials. Prospective open-label trials were found for Cutaneous Sarcoidosis, Lichen Planus, Rosacea, and Vitiligo. Individual case series and reports were found for Acrodermatitis Continua of Hallopeau, Dermatomyositis, Disseminated Granuloma Annulare, Erythema Nodosum Leprosum, Morphea, Pityriasis Rubra Pilaris, Hailey-Hailey Disease, Recurrent Erythema Multiforme, and Folliculitis Decalvans, Prurigo Nodularis, Perforating Dermatoses, Chronic Actinic Dermatitis, and Hand Eczema, and Epidermolysis Bullosa Simplex-Generalised Severe Type. Apremilast has shown varied efficacy despite a better safety profile and tolerability over a long duration compared to conventional immunosuppressant drugs and placebo. Conclusion: Apremilast has been used for varied non-FDA-approved indications in dermatology with variable efficacy. Better controlled, randomized studies with adequate sample size and drug comparisons are needed for better analyses.

show abstract

Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study

Cited by 13 publications

References 5 publications

Comparison of NB‐UVB combination therapy regimens for vitiligo: A systematic review and network meta‐analysis

Comparison of NB‐UVB combination therapy regimens for vitiligo: A systematic review and network meta‐analysis

Evolving utility of apremilast in dermatological disorders for off-label indications

Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature

Contact Info

Product

Resources

About